Shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) were down 4.4% during trading on Thursday . The stock traded as low as $15.30 and last traded at $15.53, with a volume of 216,096 shares changing hands. The stock had previously closed at $16.24.

Several analysts recently commented on FLXN shares. Wells Fargo & Co. started coverage on Flexion Therapeutics in a report on Tuesday, May 3rd. They issued an “outperform” rating on the stock. BMO Capital Markets started coverage on Flexion Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $35.00 target price on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $44.00 target price on shares of Flexion Therapeutics in a report on Friday, March 11th. Royal Bank Of Canada reiterated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, June 30th. Finally, Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $31.81.

The stock has a 50-day moving average price of $14.58 and a 200-day moving average price of $12.83. The firm’s market cap is $350.51 million.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.17. On average, equities analysts anticipate that Flexion Therapeutics Inc. will post ($2.84) earnings per share for the current fiscal year.

In other news, Director Samuel D. Colella acquired 714,285 shares of the firm’s stock in a transaction that occurred on Wednesday, June 8th. The shares were bought at an average cost of $14.00 per share, with a total value of $9,999,990.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Samuel D. Colella acquired 25,504 shares of the firm’s stock in a transaction that occurred on Tuesday, June 21st. The shares were purchased at an average cost of $13.71 per share, for a total transaction of $349,659.84. Following the completion of the acquisition, the director now owns 3,435 shares in the company, valued at approximately $47,093.85. The disclosure for this purchase can be found here.

Several institutional investors have recently made changes to their positions in FLXN. Jennison Associates LLC boosted its position in shares of Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock worth $56,032,000 after buying an additional 76,487 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock worth $9,061,000 after buying an additional 81,500 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock worth $8,296,000 after buying an additional 59,866 shares in the last quarter. Oxford Asset Management purchased a new position in shares of Flexion Therapeutics during the fourth quarter worth $1,901,000. Finally, Jennison Associates boosted its position in shares of Flexion Therapeutics by 35.1% in the third quarter. Jennison Associates now owns 2,831,268 shares of the specialty pharmaceutical company’s stock worth $42,073,000 after buying an additional 736,261 shares in the last quarter.

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.